Review
Pharmacology & Pharmacy
Wenbing Hua, Zhengmei Huang, Zhuoli Huang
Summary: This systematic review found that patients receiving uninterrupted DOAC therapy may have a lower risk of bleeding after dental extraction. However, due to the limited quality of the evidence, the results should be interpreted with caution. Further studies with larger sample sizes are needed to support these conclusions.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Hematology
Emmanouela Kampouraki, Peter Avery, Tina Biss, Hilary Wynne, Farhad Kamali
Summary: The study found that there is significant variability in drug exposure among elderly patients receiving direct oral anticoagulants (DOACs), with factors such as dosage, renal function, and gender contributing to a third of the variability in DOAC plasma concentrations. Further investigation is needed to determine whether the observed increase in DOAC exposure in older patients is the cause of their increased risk of bleeding, which could potentially be alleviated through dosing titration.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Hematology
Melina Verso, Michela Giustozzi, Alessandra Vinci, Laura Franco, Maria Cristina Vedovati, Emanuela Marchesini, Cecilia Becattini, Giancarlo Agnelli
Summary: This study identified risk factors for DOAC-associated gastrointestinal bleeding (GIB), including active cancer, renal impairment, bleeding predisposition, COPD, and uncontrolled hypertension. Adjusted one-year mortality was significantly higher in patients with DOAC-associated GIB compared to those without GIB.
THROMBOSIS RESEARCH
(2021)
Article
Hematology
Luise Adam, Martin Feller, Lamprini Syrogiannouli, Cinzia Del-Giovane, Jacques Donze, Christine Baumgartner, Daniel Segna, Carmen Floriani, Laurent Roten, Urs Fischer, Stefanie Aeschbacher, Giorgio Moschovitis, Jurg Schlapfer, Dipen Shah, Peter Amman, Richard Kobza, Matthias Schwenkglenks, Michael Kuehne, Leo H. Bonati, Jurg Beer, Stefan Osswald, David Conen, Drahomir Aujesky, Nicolas Rodondi
Summary: This study successfully developed a bleeding risk prediction model for AF patients on oral anticoagulants, with factors such as age over 75 years, history of cancer, prior major hemorrhage, and arterial hypertension included in the final prediction model. The model showed good calibration and discrimination with a Brier score of 0.23 and a c-statistic of 0.71 at 12 months follow-up.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Multidisciplinary Sciences
Gwang-Un Kim, Sinwon Lee, Jaewon Choe, Sung Wook Hwang, Sang Hyoung Park, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Dong-Hoon Yang
Summary: A retrospective study compared the outcomes of patients taking DOACs and clopidogrel after polypectomy, finding that the risk of delayed PPB was not greater in those taking DOACs than in those taking clopidogrel.
SCIENTIFIC REPORTS
(2021)
Review
Medicine, General & Internal
Rachel P. Rosovsky, Eva Kline-Rogers, Leslie Lake, Tracy Minichiello, Gregory Piazza, Bishoy Ragheb, Beth Waldron, Daniel M. Witt, Stephan Moll
Summary: In clinical practice, direct oral anticoagulants (DOACs) are used for venous thromboembolism treatment and prevention. The use of DOACs in obese patients is still controversial, with limited supporting data previously. There are also evidence gaps regarding the treatment of severe obesity and the appropriate use of DOACs in different situations.
AMERICAN JOURNAL OF MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Enrique Rodriguez de Santiago, Ruben Sanchez Aldehuelo, Fausto Riu Pons, Carlos Rodriguez Escaja, Gloria Fernandez-Esparrach, Angel Canete-Ruiz, Carlos Ferre Aracil, Daniel Perez-Corte, Raquel Rios Leon, Hector Miguel Marcos-Prieto, Pedro G. Delgado-Guillena, Ana Garcia-Rodriguez, Charly Guarner-Argente, Alfonso Muriel, Elsa de la Fuente-Briongos, Ana Garcia Garcia de Paredes, Sofia Parejo-Carbonell, Luis Tellez, Carla Senosiain-Lalastra, Diego Burgos-Santamaria, Marta Aicart-Ramos, Beatriz Mateos Munoz, Beatriz Penas-Garcia, Giulia Pagano, Gemma Casals Urquiza, Miguel Urpi Ferreruela, Miguel Angel de Jorge-Turrion, Eva Barreiro-Alonso, Miguel Fraile-Lopez, Ana Gomez-Outomuro, Maria Isabel Altamirano, Matilde Nunez Esteban, Mireia Ruiz-Andreu, Julia Arribas-Anta, Diego de Frutos, Alberto Herreros-de-Tejada, Maria Luisa Arias-Rivera, Marta Roldan-Fernandez, Angel F. Marcos Martin, Javier Zamora, Enrique Vazquez-Sequeiros, Agustin Albillos
Summary: This study found that the risks of endoscopy-related gastrointestinal bleeding and thromboembolic events were similar in patients undergoing elective endoscopy on DOACs or VKAs. Early anticoagulant resumption appeared to be safe in most patients, but further research is needed for high-risk therapeutic procedures.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Hematology
Matteo Candeloro, Nick van Es, Nathan Cantor, Sam Schulman, Marc Carrier, Walter Ageno, Jesus Aibar, Marco Paolo Donadini, Roisin Bavalia, Marie-Pier Arsenault, Michiel Coppens, Noemi Ferrante, Andrea D'Addezio, Stefano Sormani, Ettore Porreca, Marcello Di Nisio
Summary: Anticoagulant treatment after gastrointestinal bleeding is associated with a lower risk of thromboembolism and death, but higher risk of recurrent bleeding. The risk of recurrent bleeding is influenced more by patient characteristics than by the timing of anticoagulation resumption.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Review
Cardiac & Cardiovascular Systems
Robert Benamouzig, Maxime Guenoun, David Deutsch, Laurent Fauchier
Summary: There is no significant difference in major gastrointestinal bleeding risk between DOACs and VKAs. Gastrointestinal bleeding in DOAC-treated patients appears to be less severe and requires less intensive management. The main causes of gastrointestinal bleeding in DOAC-treated patients differ between upper and lower gastrointestinal bleeding.
CARDIOVASCULAR DRUGS AND THERAPY
(2022)
Article
Pharmacology & Pharmacy
Allison Cid, Megan E. Smetana, Courtney Hebert, Kelci Coe, Jessica M. Smith
Summary: The aim of this study was to evaluate the effect of concomitant use of fluconazole and direct oral anticoagulants (DOACs) on bleeding risk. The study found that patients receiving a DOAC with fluconazole did not have a significantly increased risk for bleeding at 30 days compared to those receiving a DOAC alone after adjusting for confounding variables.
Article
Hematology
Nour Al-Hussainy, Kristian Hay Kragholm, Soren Lundbye-Christensen, Christian Torp-Pedersen, Manan Pareek, Susette Krohn Therkelsen, Gregory Y. H. Lip, Sam Riahi
Summary: The use of certain direct oral anticoagulants (DOACs) may increase the risk of gastrointestinal bleeding, especially in patients with anemia. This study investigated the differences in the risks of gastrointestinal bleeding and stroke among the four available DOACs in atrial fibrillation patients with moderate or severe anemia. The results showed that apixaban was associated with a significantly lower risk of gastrointestinal bleeding compared to dabigatran and rivaroxaban, while no significant difference in stroke risk was observed among all four DOACs.
THROMBOSIS RESEARCH
(2023)
Review
Clinical Neurology
Shadi Yaghi, Ian J. Saldanha, Chelsea Misquith, Bashar Zaidat, Asghar Shah, Kareem Joudi, Bianca Persaud, Feras Abdul Khalek, Liqi Shu, Adam de Havenon, Eva A. Mistry, Ekaterina Bakradze, Eric D. Goldstein, John Reagan, Aikaterini Theodorou, Lina Palaiodimou, Karen Furie, Thalia S. Field, Georgios Tsivgoulis, Brian Mac Grory
Summary: This systematic review and meta-analysis suggest that DOACs and warfarin may have comparable efficacy and safety in patients with cerebral venous thrombosis. However, due to the limitations of the included studies, caution should be exercised in interpreting these findings until confirmation is obtained from ongoing randomized controlled trials and large, prospective, observational studies.
Article
Pharmacology & Pharmacy
Andrew Willeford, Wenhong Zhu, Craig Stevens, Isac C. Thomas
Summary: DOACs may be reasonable alternatives for the treatment of LV thrombus, but showed no significant difference in efficacy compared to warfarin. Randomized clinical trials are needed in the future to further validate efficacy.
ANNALS OF PHARMACOTHERAPY
(2021)
Article
Pharmacology & Pharmacy
Jeong Yee, Tae-Jin Song, Ha-Young Yoon, Junbeom Park, Hye-Sun Gwak
Summary: The purpose of this study was to identify genetic factors related to the renin-angiotensin system (RAS) and its association with bleeding, and to develop a risk scoring system for bleeding in patients receiving direct oral anticoagulants (DOACs). The study found that older age and moderate to severe renal impairment were independent risk factors for bleeding, and certain RAS-related gene polymorphisms were also associated with increased bleeding risk. According to the risk scoring system, the risk of bleeding increased exponentially with a higher score.
Article
Gastroenterology & Hepatology
Natalie Tapaskar, Sandra A. Ham, Dejan Micic, Neil Sengupta
Summary: Resumption of warfarin or DOAC after hospitalization for gastrointestinal bleeding is associated with a decreased risk of thromboembolism, while resumption of warfarin and rivaroxaban is associated with an increased risk of recurrent GI bleeding.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Letter
Medicine, General & Internal
Marco Montagna, Nuccia Morici, Tobias Tritschler, Patrizia Rovere Querini
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2023)
Review
Pediatrics
Shelley M. Vanderhout, Manav Bhalla, Alicia Van, Dean A. Fergusson, Beth K. Potter, Aliza Karoly, Valentina Ly, Colin Macarthur
Summary: This scoping review examined the impacts of patient and family engagement on child health research. It found that engagement has significant effects on the research process, research teams, and patient and family partners. However, the evaluation of these impacts is rare, highlighting the need for systematic and standardized evaluation.
JOURNAL OF PEDIATRICS
(2023)
Meeting Abstract
Hematology
Faizan Khan, Doug Coyle, Kednapa Thavorn, Sasha van Katwyk, Tobias Tritschler, Brian Hutton, Gregoire Le Gal, Marc A. Rodger, Dean Fergusson
Article
Hematology
Carla Schenker, Odile Stalder, Marie Mean, Tobias Tritschler, Marc Righini, Nicolas Rodondi, Drahomir Aujesky
Summary: The underrepresentation of older patients with VTE in clinical anticoagulation trials is a problem. This study examined the exclusion of elderly patients and compared bleeding risks between excluded and enrolled patients. The study found that about one-third of older patients would be excluded from participation in these trials, and the bleeding risk increases with the number of exclusion criteria.
THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Medicine, General & Internal
Faizan Khan, Kednapa Thavorn, Doug Coyle, Sasha van Katwyk, Tobias Tritschler, Brian Hutton, Gregoire Le Gal, Marc Rodger, Dean Fergusson
Summary: This study aims to assess the differences in clinical benefits, harms, and costs of stopping versus continuing anticoagulant therapy indefinitely for a first unprovoked venous thromboembolism (VTE). A probabilistic Markov model will be developed to estimate life-years, quality-adjusted life-years, costs, and incremental cost-effectiveness ratios. The results will be disseminated through conferences and a peer-reviewed journal.
Article
Medicine, General & Internal
Tracy Y. Wang, Abdus S. Wahed, Alison Morris, Lisa Baumann Kreuziger, John G. Quigley, Gervasio A. Lamas, Alexandra J. Weissman, Jose Lopez-Sendon, M. Margaret Knudson, Deborah M. Siegal, Raj S. Kasthuri, Andrew J. Alexander, Lana Wahid, Bassel Atassi, Peter J. Miller, Janice W. Lawson, Bela Patel, Jerry A. Krishnan, Nancy L. Shapiro, Deborah E. Martin, Andrei L. Kindzelski, Eric S. Leifer, Jungnam Joo, Lingyun Lyu, Annie Pennella, Brendan M. Everett, Mark W. Geraci, Kevin J. Anstrom, Thomas L. Ortel
Summary: This study aimed to determine whether anticoagulation is effective in reducing death and thromboembolic complications among patients discharged after COVID-19 hospitalization. The study was terminated early due to a lower-than-expected event rate and declining COVID-19 hospitalizations, leading to inconclusive results.
ANNALS OF INTERNAL MEDICINE
(2023)
Review
Multidisciplinary Sciences
Sylvain Boet, Cole Etherington, Pierre-Marc Dion, Chloe Desjardins, Manvinder Kaur, Valentina Ly, Manon Denis-LeBlanc, Cecile Andreas, Abi Sriharan
Summary: Physician wellness is crucial for patient safety and quality care. This review examines the impact of coaching by trained coaches on physician well-being, distress, and burnout. The evidence suggests that coaching for physicians can improve their well-being and reduce distress and burnout.
Article
Hematology
Jan O. Gaugler, Marc Righini, Helia Robert-Ebadi, Olivier Sanchez, Pierre-Marie Roy, Franck Verschuren, Sebastien Miranda, Aurelien Delluc, Gregoire Le Gal, Tobias Tritschler
Summary: This study evaluated the association between obesity and body mass index (BMI) with confirmed pulmonary embolism (PE) in patients with suspected PE and assessed the efficiency and safety of the age-adjusted D-dimer strategy in obese patients. The results showed that BMI and obesity were not associated with confirmed PE. The use of the age-adjusted D-dimer strategy increased the proportion of obese patients in whom PE was considered ruled out without imaging.
THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Hematology
Kristina Vrotniakaite-Bajerciene, Tobias Tritschler, Katarzyna Aleksandra Jalowiec, Helen Broughton, Fabienne Schmidli, Jenny Sarah Schneider, Alan Haynes, Alicia Rovo, Johanna Anna Kremer Hovinga, Drahomir Aujesky, Anne Angelillo-Scherrer
Summary: This study aimed to investigate the adherence to thrombophilia testing guidelines, its therapeutic impact, and identify the patients' clinical characteristics mostly associated with treatment decisions. The findings showed poor adherence to the guidelines and no impact on treatment decisions. Therefore, refinement of selection criteria is needed to increase the therapeutic impact of thrombophilia testing.
THROMBOSIS RESEARCH
(2023)
Article
Anesthesiology
Deborah M. Siegal, Emilie P. Belley-Cote, Shun Fu Lee, Tara Robertson, Stephen Hill, Pamela Benoit, Brandi Meeks, Julian Owen, Tanya Roglich, Elena Zotova, Stuart J. Connolly
Summary: The study aimed to assess the feasibility of using small-volume tubes for blood sampling to reduce transfusion in intensive care unit patients. The results showed that the implementation of small-volume tubes was feasible and did not increase the frequency of inadequate samples. These findings provide valuable insights for further research on the potential of small-volume tubes in reducing transfusion.
CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE
(2023)
Article
Cardiac & Cardiovascular Systems
Gianluca Gazzaniga, Giovanni Amedeo Tavecchia, Francesca Bravi, Francesca Scavelli, Giovanna Travi, Gianluca Campo, Christophe Vandenbriele, Tobias Tritschler, Jonathan A. C. Sterne, Srinivas Murthy, Nuccia Morici
Summary: This meta-analysis examined the impact of antithrombotic treatment on survival of patients with acute infectious diseases. The analysis of 18 randomized controlled trials involving 16,588 patients showed that the use of antithrombotic agents was not associated with all-cause mortality in patients with infectious disease other than COVID-19.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Review
Hematology
Carla Schenker, Caterina E. Marx, Noemie Kraaijpoel, Gregoire Le Gal, Deborah M. Siegal, Frederikus A. Klok, Drahomir Aujesky, Tobias Tritschler
Summary: This study aimed to summarize definitions of fatal bleeding and describe the range of case-fatality rates of major bleeding in studies evaluating anticoagulation for venous thromboembolism (VTE). The lack of a standardized definition for fatal bleeding may lead to inaccurate estimates of the risk of fatal bleeding.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Review
Hematology
Tobias Tritschler, Anuj Patel, Noemie Kraaijpoel, Deepak L. Bhatt, Giuseppe De Luca, Pietro Di Santo, Fausto Feres, Ricardo A. Costa, Benjamin Hibbert, Takaaki Isshiki, Gregoire Le Gal, Lana A. Castellucci
Summary: The assessment of case-fatality rate (CFR) of major bleeding in patients receiving dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is important for understanding the risks and benefits of different durations of DAPT. This study found that the CFR of major bleeding was higher in the first 12 months of DAPT compared to long-term DAPT.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS
(2022)